SNPX: Synaptogenix Inc. Price-to-Revenue Multiple
The success of briostatin-1 will provide Synaptogenix, Inc. (SNPX) with absolute pricing power due to unique synapse regeneration. The price-to-sales multiple allows for an assessment of the business's market value, with the 0.00 mark indicating the current metric level. Primary threats are linked to potential trial failures and a dependence on investment. The operating model relies on external contractors to conduct clinical trials.
Neurotrope (SNPX) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization information:
- book capitalization data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Synaptogenix, Inc.|SNPX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio Synaptogenix, Inc|SNPX - Company Total Debt|Debt to Net Assets Ratio Neurotrope|SNPX - Company Long-Term Debts|Short-Term Debt Volume Synaptogenix|Immediate Liquidity Ratio synaptogen.com
- earnings and multiples data:
SNPX - Net Profit|Future Profit Synaptogenix, Inc.|SNPX - Price to Earnings Ratio|Market Cap to Projected Earnings Synaptogenix Inc.|SNPX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Neurotrope|SNPX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Synaptogenix|SNPX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months synaptogen.com|SNPX - Net earnings per share growth this year|Projected earnings per share growth rate for next year Synaptogenix, Inc.
- total revenue and sales volume data:
Summary company analytics:synaptogen.com, SNPX
A fundamental valuation of Synaptogenix, Inc. (SNPX) through risk minimization requires an analysis of capitalization efficiency relative to revenue, which is particularly critical given the high costs of laboratory environmental upgrades and energy conservation. The ratio of market value to sales volume, reflected in the price-to-sales multiple, demonstrates how much an investor is willing to pay per unit of revenue, determining the degree of overvaluation or the growth potential of the company's assets.
Competing companies
BIIB - Price to Sales|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Price-to-Revenue Multiple Regencell Bioscience Ltd|Axsome Therapeutics Inc - P/S Multiple|Price to Sales ACADIA Corp|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Catalyst Pharma (CPRX) - Price-to-Revenue Coefficient|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Harmony Corp - Market Cap to Revenue Ratio|Biohaven Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|Market Cap to Revenue Alector Therapeutics (ALEC)|Market Cap to Revenue ANNX (Annexon)|Price-to-Revenue Coefficient omeros.com|Price-to-Revenue Ratio Neurogene Corp NGNE|Price-to-Revenue Coefficient AC Immune Inc (ACIU)|VYGR - Price-to-Revenue Ratio|NMRA (neumoratx.com) - Market Cap to Revenue Ratio|Scilex (SCLX) - Price-to-Revenue Ratio|Price-to-Sales Ratio TVGN (Tevogen Bio Holdings Inc.)|Market Cap to Revenue ACOG|Market Cap to Revenue Ratio CGTX (Cognition Therapeutics Inc.)|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|cassavasciences.com - Market Cap to Revenue Ratio|P/S Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Sales|VTGN: Market Cap to Revenue|OVID - P/S Multiple|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|cervomed.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Price to Sales Clene Nanomedicine CLNN|Price-to-Revenue Ratio PepGen Inc. (PEPG)|Price-to-Revenue Coefficient Jupiter Neurosciences, Inc.|Relmada Therapeutics - Market Cap to Revenue|annovisbio.com (ANVS) - Price to Sales|GRCE - Price-to-Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals|MetaVia, Inc. - Price-to-Sales Ratio|Market Cap to Revenue NRXS (NeurAxis)|Market Cap to Sales Volume HSDT|Price-to-Revenue Ratio Passage Bio PASG|Neuphoria Therapeutics, Inc. (NEUP) - Price to Sales|Minerva Neurosciences - P/S Multiple|Price-to-Revenue Multiple athira.com (ATHA)|ADXN: P/S Multiple|Price to Sales Alzamend Neuro (ALZN)|Price-to-Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Revenue Ratio PTIX (Protagenic)|P/S Multiple KTTA|Price-to-Revenue Coefficient cortigent.com|Avenue Therapeutics, Inc. - Market Cap to Revenue|BCLI: Market Cap to Revenue Ratio|CARA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CHRO (Chromocell)|ELYM: P/S Multiple|ITCI - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Longboard Pharmaceuticals, Inc.|Market Cap to Revenue Ratio MRNS (Marinus Pharmaceuticals Inc)|P/S Multiple NKGN|Market Cap to Revenue NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient trevena.com (TRVN)|VIGL - Price-to-Revenue Ratio|Price-to-Revenue Coefficient anewmeds.com WENA|Cerevel (CERE) - Price-to-Revenue Ratio
